ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Study Number: 

PH 246213

Phase: 
Early Phase
Trial categories: 
Bladder
Urothelial, Transitional Cell
Metastatic or Unresectable
Immunotherapy
Antibody therapy
Principal Investigator: